544 related articles for article (PubMed ID: 31065847)
1. Relationship between clinical features, GEP class, and PRAME expression in uveal melanoma.
Schefler AC; Koca E; Bernicker EH; Correa ZM
Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1541-1545. PubMed ID: 31065847
[TBL] [Abstract][Full Text] [Related]
2. Gene Expression Profiling and PRAME Status Versus Tumor-Node-Metastasis Staging for Prognostication in Uveal Melanoma.
Cai L; Paez-Escamilla M; Walter SD; Tarlan B; Decatur CL; Perez BM; Harbour JW
Am J Ophthalmol; 2018 Nov; 195():154-160. PubMed ID: 30092184
[TBL] [Abstract][Full Text] [Related]
3. CORRELATION OF GENE EXPRESSION PROFILE STATUS AND AMERICAN JOINT COMMISSION ON CANCER STAGE IN UVEAL MELANOMA.
Berry DE; Schefler AC; Seider MI; Materin M; Stinnett S; Mruthyunjaya P;
Retina; 2020 Feb; 40(2):214-224. PubMed ID: 31972790
[TBL] [Abstract][Full Text] [Related]
4. Gene Expression Profiling Prognostication of Posterior Uveal Melanoma: Does Size Matter?
Binkley EM; Bena JF; Davanzo JM; Hinz C; Boldt HC; Singh AD
Ophthalmol Retina; 2020 Jun; 4(6):620-629. PubMed ID: 32081600
[TBL] [Abstract][Full Text] [Related]
5. PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma.
Field MG; Decatur CL; Kurtenbach S; Gezgin G; van der Velden PA; Jager MJ; Kozak KN; Harbour JW
Clin Cancer Res; 2016 Mar; 22(5):1234-42. PubMed ID: 26933176
[TBL] [Abstract][Full Text] [Related]
6. Association between traditional clinical high-risk features and gene expression profile classification in uveal melanoma.
Nguyen BT; Kim RS; Bretana ME; Kegley E; Schefler AC
Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):421-427. PubMed ID: 29185101
[TBL] [Abstract][Full Text] [Related]
7. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
[TBL] [Abstract][Full Text] [Related]
8. RELATIONSHIP OF CLINICAL FEATURES AND BASELINE TUMOR SIZE WITH GENE EXPRESSION PROFILE STATUS IN UVEAL MELANOMA: A Multi-institutional Study.
Berry D; Seider M; Stinnett S; Mruthyunjaya P; Schefler AC;
Retina; 2019 Jun; 39(6):1154-1164. PubMed ID: 29578940
[TBL] [Abstract][Full Text] [Related]
9. Preferentially Expressed Antigen in Melanoma Immunohistochemistry Labeling in Uveal Melanomas.
Ahmadian SS; Dryden IJ; Naranjo A; Toland A; Cayrol RA; Born DE; Egbert PS; Brown RA; Mruthyunjaya P; Lin JH
Ocul Oncol Pathol; 2022 Jun; 8(2):133-140. PubMed ID: 35959159
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas.
Field MG; Durante MA; Decatur CL; Tarlan B; Oelschlager KM; Stone JF; Kuznetsov J; Bowcock AM; Kurtenbach S; Harbour JW
Oncotarget; 2016 Sep; 7(37):59209-59219. PubMed ID: 27486988
[TBL] [Abstract][Full Text] [Related]
11. Association of Ultrasound Features in Uveal Melanoma With Metastatic Risk as Defined by Preferentially Expressed Antigen in Melanoma Status.
Rusakevich AM; Schefler AC; Zhou B; Brown A; Robe C; Bretana ME
Ophthalmic Surg Lasers Imaging Retina; 2022 Jul; 53(7):374-378. PubMed ID: 35858230
[TBL] [Abstract][Full Text] [Related]
12. Independent Prognostic Significance of Gene Expression Profile Class and Largest Basal Diameter of Posterior Uveal Melanomas.
Corrêa ZM; Augsburger JJ
Am J Ophthalmol; 2016 Feb; 162():20-27.e1. PubMed ID: 26596399
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Implications of Tumor Diameter in Association With Gene Expression Profile for Uveal Melanoma.
Walter SD; Chao DL; Feuer W; Schiffman J; Char DH; Harbour JW
JAMA Ophthalmol; 2016 Jul; 134(7):734-40. PubMed ID: 27123792
[TBL] [Abstract][Full Text] [Related]
14. New concepts in the molecular understanding of uveal melanoma.
Reichstein D
Curr Opin Ophthalmol; 2017 May; 28(3):219-227. PubMed ID: 28257297
[TBL] [Abstract][Full Text] [Related]
15. Validation of the Prognostic Usefulness of the Gene Expression Profiling Test in Patients with Uveal Melanoma.
Miguez S; Lee RY; Chan AX; Demkowicz PC; Jones BSCL; Long CP; Abramson DH; Bosenberg M; Sznol M; Kluger H; Goldbaum MH; Francis JH; Pointdujour-Lim R; Bakhoum MF
Ophthalmology; 2023 Jun; 130(6):598-607. PubMed ID: 36739981
[TBL] [Abstract][Full Text] [Related]
16. Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma.
Onken MD; Worley LA; Char DH; Augsburger JJ; Correa ZM; Nudleman E; Aaberg TM; Altaweel MM; Bardenstein DS; Finger PT; Gallie BL; Harocopos GJ; Hovland PG; McGowan HD; Milman T; Mruthyunjaya P; Simpson ER; Smith ME; Wilson DJ; Wirostko WJ; Harbour JW
Ophthalmology; 2012 Aug; 119(8):1596-603. PubMed ID: 22521086
[TBL] [Abstract][Full Text] [Related]
17. Association between Tumor Regression Rate and Gene Expression Profile after Iodine 125 Plaque Radiotherapy for Uveal Melanoma.
Mruthyunjaya P; Seider MI; Stinnett S; Schefler A;
Ophthalmology; 2017 Oct; 124(10):1532-1539. PubMed ID: 28549517
[TBL] [Abstract][Full Text] [Related]
18. Driver Mutations in Uveal Melanoma: Associations With Gene Expression Profile and Patient Outcomes.
Decatur CL; Ong E; Garg N; Anbunathan H; Bowcock AM; Field MG; Harbour JW
JAMA Ophthalmol; 2016 Jul; 134(7):728-33. PubMed ID: 27123562
[TBL] [Abstract][Full Text] [Related]
19. Relationship between rate of posterior uveal melanoma flattening following plaque radiotherapy and gene expression profile class of tumor cells.
Corrêa ZM; Augsburger JJ
Invest Ophthalmol Vis Sci; 2014 Jan; 55(1):556-9. PubMed ID: 24408979
[TBL] [Abstract][Full Text] [Related]
20. A prognostic test to predict the risk of metastasis in uveal melanoma based on a 15-gene expression profile.
Harbour JW
Methods Mol Biol; 2014; 1102():427-40. PubMed ID: 24258991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
